Meeting
2023 ASCO Annual Meeting
Risk of further progression or death among durable progression-free survivors with melanoma in PD-1 blockade trials: Implications for imaging surveillance.
Authors
Lei Deng
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Lei Deng , Changchuan Jiang , Kristopher Attwood , Stuthi Perimbeti , Chen Hu , Igor Puzanov
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9529)
DOI
10.1200/JCO.2023.41.16_suppl.9529
Abstract #
9529
Poster Bd #
292
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Receipt of recommended surveillance with imaging in survivors of early stage non-small cell lung cancer.
First Author: Jyoti Malhotra
Poster
2017 ASCO Annual Meeting
Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.
First Author: Louise Sayers
Poster
2012 ASCO Quality Care Symposium
Use of advanced imaging and biomarker tests for post-treatment surveillance in early-stage breast cancer survivors.
First Author: Erin Hahn
Poster
2024 ASCO Annual Meeting
ADU-1604, a novel CTLA-4 blocking antibody, to modulate pharmacodynamic markers in patients with PD1 relapse/refractory melanoma.
First Author: Guillermo De Velasco